X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 17.8 13.6 130.6% View Chart
P/BV x 5.8 3.8 151.5% View Chart
Dividend Yield % 0.4 0.3 107.7%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5411,262 122.1%   
Low Rs582672 86.7%   
Sales per share (Unadj.) Rs237.5270.6 87.8%  
Earnings per share (Unadj.) Rs33.924.9 136.2%  
Cash flow per share (Unadj.) Rs40.634.4 117.9%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.20.2 113.9%  
Book value per share (Unadj.) Rs120.6151.3 79.7%  
Shares outstanding (eoy) m585.17282.16 207.4%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.53.6 125.1%   
Avg P/E ratio x31.338.9 80.6%  
P/CF ratio (eoy) x26.228.1 93.1%  
Price / Book Value ratio x8.86.4 137.8%  
Dividend payout %7.48.0 91.8%   
Avg Mkt Cap Rs m621,041272,778 227.7%   
No. of employees `00013.310.0 132.5%   
Total wages/salary Rs m15,50813,782 112.5%   
Avg. sales/employee Rs Th10,457.67,614.9 137.3%   
Avg. wages/employee Rs Th1,167.11,374.8 84.9%   
Avg. net profit/employee Rs Th1,491.6700.2 213.0%   
INCOME DATA
Net Sales Rs m138,96176,340 182.0%  
Other income Rs m1,663356 466.8%   
Total revenues Rs m140,62476,696 183.4%   
Gross profit Rs m32,05614,172 226.2%  
Depreciation Rs m3,9262,691 145.9%   
Interest Rs m2,5681,789 143.5%   
Profit before tax Rs m27,22510,048 271.0%   
Minority Interest Rs m390-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,4443,028 245.8%   
Profit after tax Rs m19,8207,019 282.4%  
Gross profit margin %23.118.6 124.3%  
Effective tax rate %27.330.1 90.7%   
Net profit margin %14.39.2 155.1%  
BALANCE SHEET DATA
Current assets Rs m100,01559,096 169.2%   
Current liabilities Rs m74,75940,018 186.8%   
Net working cap to sales %18.225.0 72.7%  
Current ratio x1.31.5 90.6%  
Inventory Days Days10775 143.3%  
Debtors Days Days110119 91.9%  
Net fixed assets Rs m52,35039,075 134.0%   
Share capital Rs m585282 207.4%   
"Free" reserves Rs m67,70730,281 223.6%   
Net worth Rs m70,56742,703 165.3%   
Long term debt Rs m8,47224,873 34.1%   
Total assets Rs m156,994111,026 141.4%  
Interest coverage x11.66.6 175.4%   
Debt to equity ratio x0.10.6 20.6%  
Sales to assets ratio x0.90.7 128.7%   
Return on assets %14.37.9 179.8%  
Return on equity %28.116.4 170.9%  
Return on capital %37.717.5 215.5%  
Exports to sales %51.043.3 117.9%   
Imports to sales %18.87.4 253.7%   
Exports (fob) Rs m70,92733,044 214.6%   
Imports (cif) Rs m26,1935,672 461.8%   
Fx inflow Rs m71,01536,945 192.2%   
Fx outflow Rs m28,79961,066 47.2%   
Net fx Rs m42,216-24,122 -175.0%   
CASH FLOW
From Operations Rs m17,5963,449 510.2%  
From Investments Rs m-13,801-8,802 156.8%  
From Financial Activity Rs m-1986,986 -2.8%  
Net Cashflow Rs m3,597934 385.2%  

Share Holding

Indian Promoters % 54.1 48.3 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 6.9 115.2%  
FIIs % 27.7 34.4 80.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 56,727 122.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  SUN PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 22, 2017 03:36 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS